Bound, free, and total l-dopa measurement in plasma of Parkinson’s disease patients

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

(2019) Sebastiaan P. van Kessel et al.   Nature Communications

Pill swallowing in Parkinson's disease: A prospective study based on flexible endoscopic evaluation of swallowing

(2019) Carsten Buhmann et al.   PARKINSONISM & RELATED DISORDERS

Long-term management of Parkinson’s disease using levodopa combinations

(2018) Thomas Müller et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs

(2017) Yuval Ramot et al.   TOXICOLOGIC PATHOLOGY

Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC–MS/MS method

(2015) Rômulo Pereira Ribeiro et al.   Bioanalysis

Binding studies of l-3,4-dihydroxyphenylalanine with human serum albumin

(2014) Daniel Pushparaju Yeggoni et al.   Molecular BioSystems

Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease

(2013) Thomas Müller   CLINICAL NEUROPHARMACOLOGY

Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion

(2007) Birgit Meiler et al.   MOVEMENT DISORDERS